[Translation] A multicenter, randomized, double-blind, dose-finding phase II study of VEGFR2 (KDR) ultrasound molecular imaging using BR55 in patients with cancer and chronic inflammatory diseases
主要目的:通过比较3种剂量的研究产品的增强效果,以免疫组化(IHC)作为金标准,在已知或疑似诊断为癌症(乳腺癌、甲状腺癌和卵巢癌)或慢性炎症性疾病(IBD和RA)的患者中,确定BR55用于超声成像评估血管生成区域的剂量。
[Translation] Main objective: To compare the potentiation effect of 3 doses of investigational product, using immunohistochemistry (IHC) as the gold standard, in patients with known or suspected diagnosis of cancer (breast, thyroid and ovarian) or chronic inflammatory disease ( In patients with IBD and RA), the dose of BR55 was determined for the assessment of angiogenic areas by ultrasound imaging.